

CAPABILITY STATEMENT



Core Competency

RC21X has created an advanced cloud-based technology for measuring and monitoring key neurocognitive and neuromotor brain performance capabilities. The patent-pending platform uses an intuitive, game-like experience that encourages repeated use across a person's lifespan and is a "web-ified" version of tests and apparatuses widely used to measure neurocognitive and neuromotor performance. RC21X provides rapid performance measurement and assessment solutions.



RC21X's mobile app (Roberto) provides performance trend data in real time. Each session takes only 6 minutes and generates 1,500 data points.

We team with companies that are committed to improving safety and production in often high-risk industry sectors. RC21X's technology sets a new workplace safety standard through regular human performance assessments. The result: lower frequency and severity of accidents.

For wellness programs, RC21X brings objective data that can be incorporated into existing plans to help assess value and overall plan performance.

Health care providers and clinicians use the RC21X platform to track and assess patients over time with solutions that facilitate reimbursement.

Company Profile

RC21X, based in Coraopolis, PA, was incorporated in the fall of 2013. The company's unique approach to monitoring and identifying human brain performance capacity uses the science of General Systems Performance Theory developed by Dr. George Kondraske, Founder and Director of the Human Performance Institute at the University of Texas at Arlington.

Differentiators

Until RC21X developed its proprietary technology, there were no consumer-friendly tools to self-assess brain performance. It remains the only platform focused on regularly measuring and assessing human performance. RC21X is designed for self-assessment and requires no clinician or administrator. Because sessions can be completed in only minutes, users can easily generate longitudinal performance data. Results are available on demand and in real time. Because the technology is cloud-based, it serves customers worldwide.

Past Performance

- The RC21X platform was incorporated into an existing safety program at Illinois Marine Towing, a leading barge company, and contributed in more than \$700K in annual savings. Additionally, IMT saw recordables fall by 66 percent and lost time due to injuries decline by 75 percent.
- The RC21X platform is used by NovaCare Physical Therapy to monitor the brain performance of stroke, concussion and traumatic brain injury patients as they go through a rehabilitation plan.
- More than 700 former NFL players have been screened as part of the concussion settlement with the league. RC21X technology has correctly predicted which former athletes would be eligible for compensation with an 85-percent accuracy rate.

FDA class II medical device exemption

RC21X has been identified by the Food and Drug Administration (FDA) as a class II medical device exempt from 510(k) premarket notification requirements. RC21X is a computerized neurocognitive assessment aid that is not intended for use as a stand-alone assessment of specific diseases or conditions including PTSD, depression, ADHD and more.